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nomic model in order to evaluate the cost-effectiveness ratios between ertapenem and 
the patterns of antibiotics routinely used for the treatment of diabetic foot infections at 
the Social Security Mexican Institute (IMSS) from the health care payer’s perspective. 
METHODS: A cost-effectiveness analysis was developed using a Bayesian decision-tree 
model. The model simulates costs and effectiveness outcomes in a 4-week period. The 
comparators were: ertapenem(1 g daily); metronidazole(500 mg every 8 h)/ceftriaxone 
(1 g every 12 h); metronidazole(500 mg every 8 h)/levoﬂoxacin(500 mg every 12 h); 
metronidazole(500 mg every 8 h)/ciproﬂoxacin (500 mg every 12 h). Resource use and 
cost data were obtained from hospital (second level) records of 104 of treated patients. 
Effectiveness measures were the percentage of clinical success without adverse events 
(AE) at the end of the follow-up-period. Effectiveness data and transition probabilities 
were taken from international published literature and were adjusted according to the 
antimicrobial susceptibility identiﬁed locally. The model was calibrated according to 
international pharmacoeconomics guidelines. One-way and probabilistic sensitivity 
analyses were performed using Monte Carlo Simulation second-order approach. 
RESULTS: Patients who received ertapenem experienced 62.7% of clinical success 
without AE, followed by metronidazole/ceftriaxone (23.9%) and metronidazole/levo-
ﬂoxacin (17.8%). Mean cost per patient were lower for ertapenem (US$4306.46) fol-
lowed by metronidazole/ceftriaxone(US$8014.93) and metronidazole/levoﬂoxacin 
(US$8625.11). Based on ICER’s ertapenem resulted as the dominant therapy. Accept-
ability curves showed ertapenem as the most cost-effective therapy closer to 100% 
independently of IMSS willingness to pay. CONCLUSIONS: The results show that in 
México, ertapenem is the most cost-effective antibiotic therapy for diabetic foot infec-
tions. These results should be taken into account by Mexican decision makers for the 
management of this complication in patients with Diabetes Mellitus.
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OBJECTIVES: Case of latent tuberculosis has increased over the years as many from 
developing countries travel to the US. This study compared three CDC recommended 
regimens (Isoniazid, rifampin, and rifampin-pyrazinamide) for latent tuberculosis by 
conducting a cost effectiveness analysis taking into consideration adherence rates and 
incidence of adverse drug events. METHODS: A systematic literature review pertain-
ing to cost-effectiveness studies involving these three regimens from 1990 to 2009 was 
conducted using Pubmed. A decision tree model was developed to infer the most 
cost-effective regimen using data form randomized clinical trails. Cost in the model 
included drug cost, primary physician visit cost, follow up physician visit cost, and 
adverse drug events costs and were obtained from published literature. Rash and 
hepatotoxicity were the adverse events considered in the model as these were highly 
associated with these treatment regimens. Completion rate (adherence to the medica-
tion regimen) was the outcomes evaluated. One-way sensitivity analyses were con-
ducted by varying various costs by 10% to check for the robustness of the model. 
RESULTS: The base-case analysis revealed rifampin-pyrazinamide to be the most 
cost-effective regimen. The one-way sensitivity analysis indicated the results to be 
robust. The total cost for treatment with isoniazid was $1360.53, rifampin was 
$2111.34, and rifampin-pyrazinamid combination was $978.69. The adherence rate 
to isoniazid treatment was 53% as compared to rifampin and rifampin-pyrazinamide 
which was found to be 70% and 81% respectively. Rifampin-pyrazinamide associated 
with hepatotoxicity (4%) as compared to isoniazid (1.5%) and rifampin (3%) still 
proved cost effective. ICER for switching the treatment from rifampin-pyrazinamide 
regimen to isoniazid was $86.87 and to rifampin was $237.02. CONCLUSIONS: 
These analyses based on the data from randomized clinical trial, shows that rifampin-
pyrazinamide was indicated to be the cost effective treatment for patients with latent 
TB, as compared to isoniazid and rifampin alone.
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OBJECTIVES: Invasive Aspergillosis (IA) constitutes the most common cause of infec-
tious pneumonic mortality and represents high economic impact for patients undergo-
ing allogeneic hematopoietic stem cell transplantation and cancer, besides, it is an 
important cause of opportunistic and disseminated respiratory infections in immuno-
compromised patients. Voriconazole (VORI) and amphotericin B deoxycholate (AMB) 
are licensed antifungal therapies for primary treatment of IA, however, costs and 
efﬁcacy of these medications differ. Hypothesis: Voriconazole is cost-effective com-
pared to Amphotericin B for the treatment of IA in immunocompromised patients. 
METHODS: A decision tree (validated by one oncologist and three infectologists) was 
designed to assess cost-effectiveness of the two medications. The model simulated costs 
and effectiveness in a temporal horizon of 14 weeks. Effectiveness and outcome 
measures were deﬁned as rate of survival and life-years gained (LYs) respectively. 
Clinical efﬁcacy and node probabilities were obtained by systematic literature review 
of randomized controlled trials, which estimated direct costs associated with IA treat-
ment (antifungal drugs, hospitalization, and costs associated with adverse events). 
Medical costs from 3 major Colombian cities were used; drug costs were taken from 
a standard costing source. Incremental cost per successfully treated patient (ICERs), 
one and two-way sensitivity analyses (varying clinical success rates and costs of anti-
fungics) were performed for testing model’s robustness RESULTS: Patients treated 
with VORI experienced the highest outcomes (1.20 LYs) followed by AMB (0.68 LYs). 
Mean cost per patient was lower for AMB (US$4829) followed by VORI (US$7078). 
The C/E Rate was better for VORI (US$5896) compared to AMB (US$7036), Based 
on ICERs, VORI was cost-effective compared to AMB (ICER US$ 4374) when the 
willingness to pay threshold is US$8200 and over per patient (1 GDP per capita) 
CONCLUSIONS: Voriconazole represents the cost-effective treatment of choice when 
compared to amphotericin B deoxycholate for Invasive Aspergillosis in immunocom-
promised patients in Colombia.
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OBJECTIVES: To estimate the cost effectiveness of changing from live oral poliovirus 
vaccine to inactivated poliovirus vaccine in Colombia. METHODS: A review of sci-
entiﬁc literature on Vaccine-Associated Paralytic Poliomyelitis in Latin America was 
made. An analysis of Vaccine-Associated Paralytic Poliomyelitis of data from Colom-
bia was also realized. A Markov model was constructed to estimate the cost-effective-
ness of the two strategies in two cohorts of children ranging from birth to 2 years of 
age. The model compared the risks and costs of live oral poliovirus vaccine and 
inactivated poliovirus vaccine in the two cohorts. RESULTS: Between 1988 and 1998 
there were 9 detected cases of Vaccine-Associated Paralytic Poliomyelitis, for a rate 
of 1 per 1.6 millions in the ﬁrst dose, and 1 per 2.5 millions of total administered 
doses. The introduction of the inactivated poliovirus vaccine would prevent 1 case of 
Vaccine-Associated Paralytic Poliomyelitis every two years, and it would prevent 64 
DALY’s in each cohort of vaccinated children. Incremental cost-effectiveness ratio 
would be US$71,062 per DALY averted. CONCLUSIONS: Vaccination with inacti-
vated poliovirus vaccine is not cost-effective even assuming a substantially greater 
incidence of Vaccine-Associated Paralytic Poliomyelitis, this given a GDP per capita 
of US$8,500 in 2008.
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OBJECTIVES: Invasive candidiasis (IC) is associated with increased morbidity and 
mortality of hospitalized patients, as well as in treatment costs, which has a negative 
impact on institutional budgets. Therapeutic programs in which patients are switched 
from intravenous (IV) to oral formulations have the potential of costs reduction regard-
ing IV alone therapies. The purpose of this study was to estimate the economic and 
health consequences of IC treatment in non-neutropenic adult patients using an anti-
fungal sequential strategy, from the Instituto Mexicano del Seguro Social (IMSS) per-
spective. METHODS: A cost–effectiveness analysis was developed using a decision 
tree-model (horizon: 12 weeks). The model estimated length of stay (LOS) associated 
to IV therapies: anidulafungin (reference), ﬂuconazole, caspofungin, voriconazole, 
amphotericin B (AmB) and liposomal amphotericin (LAmB), followed by oral voricon-
azole in respondents. Efﬁcacy and safety data, as well as duration of IV phase associated 
with each therapy were extracted from published clinical trials. Resource use was col-
lected from clinical records (n = 78) at Hospital de Especialidades, Centro Médico 
Nacional “Siglo XXI” (IMSS). Unit costs were obtained from institutional sources and 
expressed in 2009 US$. Probabilistic sensitivity analysis was performed (10,000 Monte 
Carlo iterations) and acceptability curves were constructed. RESULTS: LOS (days) for 
anidulafungin, ﬂuconazole, caspofungin, voriconazole, LAmB and AmB were: 26.2, 
30.4, 27.4, 29.3, 29.8, and 30.2, respectively. Expected costs were US$27,307, 
US$32,053 (+17.4%), US$30,183 (+10.53%), US$29,457 (+8%), US$29,345 (7%) 
and US$32,906 (+21%), respectively. Stay in intensive care unit is approximately 30% 
of LOS. Due to a greater reduction in LOS and a smaller cost than competing alterna-
tives, anidulafungin + oral voriconazole strategy was dominant. Acceptability curves 
showed that, independently of willingness to pay, anidulafungin + oral voriconazole 
exhibits at least 65% probability to be cost-effective regarding competing alternatives. 
CONCLUSIONS: Anidulafungin + oral voriconazole sequential therapy to treat IC in 
non-neutropenic patients would be a cost-saving strategy at IMSS.
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OBJECTIVES: To determine the cost-effectiveness of 13-valent pneumococcal conju-
gate vaccine (PCV13) versus 7-valent pneumococcal conjugate vaccine (PCV7) and 
versus 10-valent pneumococcal conjugate vaccine (PCV10) in preventing pneumococ-
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cal disease in Singapore and Hong Kong from a payer perspective. METHODS: A 
decision-analytic model was developed to estimate the impact of vaccination with 
PCV13 relative to PCV7 and to PCV10 on invasive pneumococcal disease (IPD), 
pneumonia, and otitis media. Model inputs include disease incidence, sequelae, and 
mortality; serotype coverage; immunogenicity; direct and indirect effects; and costs. 
Speciﬁc local data were obtained from regional surveillance and published literature. 
Where local data were unavailable, proxy data were derived from published US 
sources. Vaccine costs assumed price parity to the private market unit price for PCV7 
and were based on a four dose schedule. Costs and outcomes were discounted at 3%. 
RESULTS: Preliminary results demonstrated that PCV13 was dominant compared to 
PCV10 and compared to PCV7, both with and without indirect effects, in Singapore 
and in Hong Kong. The net cost savings per child vaccinated with PCV13 compared 
to PCV7 was S$7 in Singapore and HK$1352 in Hong Kong when including indirect 
effects. With direct effects only, the net cost savings per child vaccinated was S$1 and 
HK$4 in the respective countries. PCV13 direct effects would reduce IPD by 86% 
amongst vaccinated children in both regions. Results also indicated further reductions 
in pneumonia and otitis media burden with PCV13. CONCLUSIONS: These prelimi-
nary results suggest that pediatric national immunization programs with PCV13 in 
Singapore and in Hong Kong are expected to substantially decrease pneumococcal 
illness. In addition, the programs are expected to be cost-savings relative to PCV10 
and to PCV7.
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OBJECTIVES: Determine cost-effectiveness and cost-utility of three treatment schemes 
(based on lopinavir [LPV/r], darunavir [DRV/r] and atazanavir [ATZ/r]) used in 
patients with HIV/AIDS after a ﬁrst virological failure, in Colombia. METHODS: We 
designed a Markov model with 10 six-month cycles (5-year timeframe) based on 
efﬁcacy measures obtained from published clinical trials. We estimated local direct 
costs from a payer perspective using 2009 ofﬁcial rates for drugs and lab tests, and 
real costs for AIDS-related complications (exchange rate Col$1968 per US$, January 
2010). Utilities (in QALYs) were obtained from the Tufts CEA registry. Effectiveness 
was measured as further virological failures, need of “rescue therapy”, AIDS-related 
complications, and deaths per 1000 patients (estimated through Monte Carlo proba-
bilistic simulation). We applied a 5% discount rate for costs and QALYs. RESULTS: 
Average cost per patient was US$ 39,334 for DRV/r, US$ 41,825 for LPV/r and US$ 
49,135 for ATZ/r. Five-year mortality was 5.9% in the DRV/r group, 7.6% for LPV/r 
and 8.0% for ATZ/r; there were 235 AIDS-related complications in the DRV/r group, 
383 in the LPV/r group and 326 in ATZ/r. Rescue therapy was required in 85 occa-
sions in the DRV/r group, 273 in the LPV/r group and 198 in the ATZ/r group, while 
there were 700 virological failures per 1000 patients in the DRV/r group, 1070 in 
LPV/r and 1080 in ATZ/r. Average QALYs gained in the ﬁve-year period were: DRV/r 
3.92; LPV/r 3.81 and ATZ/r 3.84. Cost-utility and cost-effectiveness analysis show 
darunavir as the dominant alternative since the ﬁrst year compared to atazanavir, and 
since the fourth year compared to lopinavir. One way sensitivity analyses did not 
modify the results signiﬁcantly. CONCLUSIONS: In Colombia, initial treatment with 
darunavir in patients with a ﬁrst antiretroviral therapy failure is less costly than with 
lopinavir or atazanavir and is signiﬁcantly more effective.
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OBJECTIVES: To evaluate the cost-effectiveness of 2009 pandemic inﬂuenza 
A(H1N1) (pH1N1) vaccination in various age and risk groups in the United States. 
METHODS: A computer simulation model was developed to predict costs and health 
outcomes for a pH1N1 vaccination program using inactivated vaccine compared to 
no vaccination. The modeled target population included hypothetical cohorts of 
persons aged 6 months and older stratiﬁed by age and risk. Probabilities, costs and 
quality-of-life weights were derived from emerging primary data on pH1N1 infections 
in the US, published and unpublished data for seasonal and pH1N1 illnesses, supple-
mented by expert opinion. The analysis used a one-year time horizon for most end-
points but also included longer-term costs and consequences of long-term sequelae 
and deaths. A societal perspective was used. The main endpoint was the incremental 
cost-effectiveness ratio in dollars per quality-adjusted life year (QALY) gained. Sensi-
tivity analyses were conducted to evaluate the robustness of results as parameters were 
varied over plausible ranges, including a scenario analysis to evaluate the effect of 
timing of vaccination assuming a hypothetical 16-week ﬂu season and normalized 
epidemic curve of illness. RESULTS: For vaccination initiated prior to the outbreak, 
pH1N1 vaccination was cost-saving for persons 6 months to 64 years with high risk 
conditions assuming a 15% overall attack rate. For those without high risk conditions, 
pH1N1 vaccination was not cost-saving but required a net investment; cost-effective-
ness ratios ranged from $8,000-$52,000/QALY depending on age and risk category. 
Results were sensitive to the number of vaccine doses needed, costs of vaccination, 
illness rates, and timing of vaccine delivery. Cost-effectiveness ratios increased sub-
stantially if vaccination were initiated after the 10th week of the start of a hypothetical 
16-week epidemic. CONCLUSIONS: Vaccination for pH1N1 for children and work-
ing-age adults is cost-effective compared to other preventive health interventions under 
a wide range of scenarios.
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OBJECTIVES: To evaluate the clinical-economic value of caspofungin therapy vs. 
standard and alternative treatments in patients with invasive candidiasis (IC) hospital-
ized in intensive care units (ICU). METHODS: The pharmacoeconomic analysis uti-
lized the cost-effectiveness analysis (CER). If the efﬁcacy and the cost of any of the 
studied regimens exceeded those of the other regimen, an incremental analysis was 
carried out (ICERs). A list of direct costs was compiled: clinical laboratory procedures 
carried out at invasive candidiasis diagnosis; antimycotic costs in the treatment of 
invasive candidiasis; antimycotic administration costs; costs of the diagnosis of adverse 
events following administration of an antimycotic. Efﬁcacy and safety data were based 
on additional analyses of a randomised, double blind, multinational trial of antimycot-
ics. To evaluate the degree of inaccuracy of the results, sensitivity analyses were 
performed RESULTS: It was established that the mode of starting treatment of IC 
amphotericin B and then caspofungin was both more effective and less expensive in 
comparison with the use of amphotericin B and then amphotericin B lipid complex. 
When we used caspofungin or amphotericin B lipid complex shares of expenses on 
antimycotices were 80–87%. Lower parameters are received at application ampho-
tericin B and ﬂuconazole, 46 % and 66 %, accordingly. The analysis of the alternative, 
whose efﬁciency of treatment of IC was equal in all groups, has shown, that the least 
expensive strategy was that where the starting therapy was amphotericin B. The 
unilateral analysis of sensitivity proves that the efﬁciency of expenses of the treatment 
of IC was more sensitive to a parameter of efﬁciency than to the change of the expenses 
connected with the price of medicines. CONCLUSIONS: In modern Russian condi-
tions, in view of a high level of resistance in vitro Candida spp. to ﬂuconazole and 
high toxicity of amphotericin B, the most expedient strategy is that starting what the 
application of caspofungin.
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OBJECTIVES: Candida species are a common cause of nosocomial bloodstream 
infection. Positive blood cultures or high clinical suspicion for candidemia prompt 
empiric antifungal therapy. Early species identiﬁcation allows earlier initiation of 
appropriate therapy or de-escalation to less expensive narrow spectrum therapy. Our 
institute used Candida PNA-FISH (Test A) to rapidly differentiate Candida albicans 
from non-albicans species. Two newer tests can differentiate among albicans, glabrata 
or others (Candida PNA-FISH dual probe, Test B) and among albicans/parapsilosis, 
tropicalis, glabrata/krusei or others (Candida PNA-FISH Trafﬁc Light, Test C). This 
study aimed to predict cost impacts if newer tests would have been used. METHODS: 
From a hospital administration perspective, a retrospective chart review of candidemic 
patients between January 2007 and May 2008 was conducted to obtain costs and 
utilization of antifungal medications and information on species identiﬁcation. Monte 
Carlo simulation models with certain assumptions and limitations were created to 
predict costs. Model inputs were determined based on real-world data. Only antifun-
gal medication costs, incorporating doses, frequencies and 2008 average wholesale 
prices, were considered. One-way and probabilistic sensitivity analyses (2,500 trials) 
were performed. RESULTS: There were 140 candidemic episodes in 132 patients. 
Candida species isolated included albicans (43%), glabrata (29%), parapsilosis (14%), 
tropicalis (6%), krusei (6%), and others. Compared to Test A, median potential cost 
savings per patient are $37 (95% CI $14-$104, Test B) and $51 (95% CI $22-$130, 
Test C). Minimal cost savings per patient are $24 (Test B) and $35 (Test C) at a 
probability of 80%. Two key variables were identiﬁed. Potential cost savings increase 
with increased empiric use of micafungin or decreased prevalence of Candida albicans. 
CONCLUSIONS: With sole consideration of antifungal medication costs, switching 
from Test A to Test C is likely to yield more cost savings than switching to Test B, 
but cost savings may not be substantial.
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OBJECTIVES: Complicated Skin and Skin Structure Infections (cSSSIs) are among 
the most common treated infections in the hospitals. Ceftobiprole has demonstrated 
efﬁcacy in treating cSSSIs in two non-inferiority trials, including those caused by 
methicillin-resistant Staphylococcus aureus (MRSA). It is currently under review 
